Arcus deprioritizes Gilead-partnered drug in prostate cancer, the latest hiccup in $1.6B collaboration

Arcus Biosciences is reducing further investment on its adenosine receptor antagonist in prostate cancer after reviewing interim data, according to its second quarter report.

In a press release Monday morning, Arcus and its partner Gilead said they reviewed progression-free survival data from a Phase Ib/II study,…
Click here to view original post

Advertisement — Advertise with Biotech Networks